Cellebrite DI Ltd. (NASDAQ:CLBT) Short Interest Update

Cellebrite DI Ltd. (NASDAQ:CLBT) was the target of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 2,480,000 shares, a decrease of 5.3% from the March 15th total of 2,620,000 shares. Approximately 4.5% of the shares of the company are sold short. Based on an average daily trading volume, of 998,300 shares, the days-to-cover ratio is currently 2.5 days.

Hedge Funds Weigh In On Cellebrite DI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CLBT. UBS Group AG bought a new stake in shares of Cellebrite DI in the 1st quarter valued at approximately $26,000. Virtus Fund Advisers LLC bought a new stake in shares of Cellebrite DI in the 4th quarter valued at approximately $28,000. Parallel Advisors LLC lifted its stake in shares of Cellebrite DI by 75.0% in the 4th quarter. Parallel Advisors LLC now owns 3,500 shares of the company’s stock valued at $30,000 after purchasing an additional 1,500 shares during the last quarter. Lazard Asset Management LLC bought a new stake in shares of Cellebrite DI in the 4th quarter valued at approximately $32,000. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Cellebrite DI by 81.4% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 7,784 shares of the company’s stock valued at $34,000 after purchasing an additional 3,494 shares during the last quarter. 45.88% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on CLBT shares. Craig Hallum increased their target price on Cellebrite DI from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. Bank of America increased their target price on Cellebrite DI from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. William Blair upgraded Cellebrite DI from a “market perform” rating to an “outperform” rating in a research report on Wednesday, March 13th. Finally, Needham & Company LLC increased their target price on Cellebrite DI from $13.00 to $13.50 and gave the stock a “buy” rating in a research report on Thursday, March 28th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $12.30.

Cellebrite DI Price Performance

Shares of Cellebrite DI stock opened at $10.38 on Thursday. The stock has a 50 day moving average of $11.19 and a 200 day moving average of $9.16. Cellebrite DI has a 12 month low of $5.22 and a 12 month high of $12.50.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Cellebrite DI had a positive return on equity of 173.14% and a negative net margin of 24.94%. The company had revenue of $93.01 million during the quarter, compared to analyst estimates of $85.43 million. As a group, analysts forecast that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.